Erivedge may cause your advanced basal cell carcinoma to shrink, or it may help control your disease
In a clinical study, 104 adults took Erivedge for their advanced basal cell carcinoma. Of the 104 patients, 96 were evaluated for overall response rate (63 were diagnosed with locally advanced basal cell carcinoma and 33 were diagnosed with metastatic basal cell carcinoma).
27 of 63 patients with locally advanced basal cell carcinoma saw their tumor shrink at 24 weeks of treatment with Erivedge. Of those 27 patients, 13 saw no visible sign of basal cell carcinoma.
10 of 33 patients with metastatic basal cell carcinoma saw their tumor shrink at 24 weeks of treatment with Erivedge. No patients in this group saw their basal cell carcinoma completely disappear.
Questions to ask your doctor
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.